Is there any role for re-biopsy and NGS for patients with NSCLC and KRAS G12C at time of progression after first line therapy before starting sotorasib, or after progression on sotorasib?
Community PollStarted
When (if at all) do you repeat NGS testing later for a patient with known KRAS G12C mutation on initial diagnostic pathology?
39 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · The Ohio State University School of Medicine
Answered on
This is a great question and one that will come up more frequently. There clearly is a role for biopsy at the time of progression on targeted therapies in other driver alterations in NSCLC, and in limited data; to date, we know that occasionally there are resistance mechanisms to KRAS inhibitors tha...
Join for free or sign in to see the full answer